Delta-Fly Pharma Inc.: Update for Expanded Phase I Study of DFP-14927

TOKUSHIMA, Japan — We are excited to share our latest development status. As informed dated October 28th, an interim analysis for the Phase III study of DFP-10917 in R/R AML patients is ongoing. The Phase I/II combination study of DFP-10917 wit

By: financialpost.com

Nov 05 2024
0
0 Views

TOKUSHIMA, Japan -- We are excited to share our latest development status. Read More

Fortis Inc. Releases Third Quarter 2024 Results

Delta-Fly Pharma Inc.: Update for Expanded Phase I Study of DFP-14927

Magna Announces New 10% Normal Course Issuer Bid and Automatic Share Purchase Plan

Probe Gold Discovers New Gold Zones, Grading up to 4.2 g/t Au over 12.8 Metres (cut), at Courvan, Novador Project, Quebec

Kremlin Oil Revenue Shrank by 29% in October Amid Lower Prices

Montage Gold Implements Revenue Protection Programme

Endeavour Silver Announces Q3 2024 Financial Results; Earnings Call at 10AM PDT (1PM EDT) Today

Northisle Announces Drill Results at Northwest Expo Including 132.8m Grading 1.49g/t Au Eq.

Diesel Set For Growing Glut as Demand Falters

Modi, Jaishankar Condemn Attack on Hindu Temple in Canada

Inflation is down, wages are up. Why are Canadians still frustrated with the economy?

B.C. ports shuttered as lockout takes hold in latest labour dispute

Share this page

Guest Posts by Easy Branches

anchor links ads by Easy Branches

Delta-Fly Pharma Inc.: Update for Expanded Phase I Study of DFP-14927

Related